Prospective randomized double-blinded placebo controlled parallel group multi-center 52-week trial

Prospective randomized double-blinded placebo controlled parallel group multi-center 52-week trial to assess the efficacy and safety of adjunct mycofenolate mofetil to achieve remission with reduced corticosteroids in subjects with active pemphigus vulgaris 1% effort 1 subject

Awarded By

  • Aspreva

Contributors

Amount

  • $9,688.00

Start/End

  • July 12, 2004 - August 1, 2006